Schwaederle M, Zhao M, Lee JJ, et al. Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials. J Clin Oncol. 2015;33(32):3817-3825.
Schwaederle M, Zhao M, Lee JJ, et al. Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis. JAMA Oncol. 2016;2(11):1452-1459.
Lynce F, Isaacs C. How far do we go with genetic evaluation? Gene, panel, and tumor testing. Am Soc Clin Oncol Educ Book. 2016;35:e72-78.
Markopoulos C, van de Velde C, Zarca D, Ozmen V, Masetti R. Clinical evidence supporting genomic tests in early breast cancer: Do all genomic tests provide the same information? Eur J Surg Oncol. 2017;43(5):909-920.
Drugs@FDA: FDA approved drug products. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Accessed April 18, 2017.
Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol. 2005;23(2):276-292.
Robson ME, Storm CD, Weitzel J, Wollins DS, Offit K. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2010;28(5):893-901.
Genetic testing for hereditary cancer syndromes. National Cancer Institute website. https://www.cancer.gov/about-cancer/causes-prevention/genetics/genetic-testing-fact-sheet. Accessed May 17, 2017.
About the Oncotype DX Breast Recurrence Score Test. Oncotype IQ website. http://www.oncotypeiq.com/en-US/breast-cancer/healthcare-professionals/oncotype-dx-breast-recurrence-score/about-the-test. Accessed May 18, 2017.
Shtivelman E. To type or to print? Oncotype DX and Mamma/BluePrint tests for breast cancer. Cancer Commons website. https://www.cancercommons.org/knowledge-blog/to-type-or-to-print-oncotype-dx-and-mammablueprint-tests-for-breast-cancer/. Published October 30, 2015. Accessed May 29, 2017.
Agarwal A, Ressler D, Snyder G. The current and future state of companion diagnostics. Pharmgenomics Pers Med. 2015;8:99-110.
Olsen D, Jorgensen JT. Companion diagnostics for targeted cancer drugs - clinical and regulatory aspects. Front Oncol. 2014;4:105.
Hirshfield KM, Tolkunov D, Zhong H, et al. Clinical actionability of comprehensive genomic profiling for management of rare or refractory cancers. Oncologist. 2016;21:1315-1325.
Answers to common questions about companion diagnostic testing for Lynparza (olaparib). FORCE: Facing Our Risk of Cancer Empowered website.
http://www.facingourrisk.org/our-role-and-impact/advocacy/documents/CompanionDiagnosticFinal.pdf. Accessed May 12, 2017.
Pant S, Weiner R, Marton MJ. Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnostics. Front Oncol. 2014;4:78.
Ritter DI, Roychowdhury S, Roy A, et al. Somatic cancer variant curation and harmonization through consensus minimum variant level data. Genome Med. 2016;8(1):117.
Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer [published online ahead of print March 2, 2017]. Nat Rev Clin Oncol. doi:10.1038/nrclinonc.2017.14.
Siu LL, Conley BA, Boerner S, LoRusso PM. Next-generation sequencing to guide clinical trials. Clin Cancer Res. 2015;21(20):4536-4544.
Do K, O'Sullivan Coyne G, Chen AP. An overview of the NCI precision medicine trials-NCI MATCH and MPACT. Chin Clin Oncol. 2015;4(3):31.
Siu LL, Lawler M, Haussler D, et al. Facilitating a culture of responsible and effective sharing of cancer genome data. Nat Med. 2016;22(5):464-471.
ASCO CancerLinQ website. http://cancerlinq.org/. Accessed May 18, 2017.
Cancer Moonshot. National Cancer Institute website. https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative. Accessed May 18, 2017.
Walder D, O'Brien M. Looking back and to the future: Are we improving 'cure' in non-small cell lung cancer? Eur J Cancer. 2017;75:192-194.
Gerber DE, Oxnard GR, Govindan R. ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer. Clin Pharmacol Ther. 2015;97(5):447-450.
Thank you for participating in this module. Click below to download the certificate.